What is the primary function of vasopressin?

Vasopressin primarily regulates water balance by increasing water reabsorption in the kidneys and maintains blood pressure through vasoconstriction.

Where is vasopressin produced?

Vasopressin is synthesized in the hypothalamus and released into the bloodstream from the posterior pituitary gland.

What are the three main types of vasopressin receptors?

The three main receptors are V1a (vascular), V1b (pituitary), and V2 (renal).

How does vasopressin affect the kidneys?

It binds to V2 receptors in the collecting ducts, triggering the translocation of aquaporin-2 channels to the cell surface, which increases water reabsorption.

Why is vasopressin used in septic shock?

Patients in septic shock often exhibit a relative deficiency of vasopressin, and its administration can help restore vascular tone and reduce the need for other vasopressors.

What is the difference between V1 and V2 receptors?

V1 receptors are primarily involved in vasoconstriction and calcium signaling, while V2 receptors are primarily involved in water reabsorption and cAMP signaling.

Back to Library

Last reviewed: October 2026

Vasopressin

Endocrine / Hormonal|Neurohypophysial peptide hormone

Also known as: Arginine vasopressin

Evidence Snapshot

PubMed-Indexed Literature

38093 exact-name search results

References Reviewed

10 indexed references used for this page

Molecular Record

No PubChem record required

Evidence Scope

The evidence landscape for vasopressin is extensive, ranging from molecular characterization of GPCR signaling to clinical applications in critical care medicine.

Key Takeaways

Vasopressin is synthesized in the hypothalamus and released in response to increased plasma osmolality or decreased arterial pressure.
The V2 receptor is primarily responsible for renal water reabsorption via the translocation of aquaporin-2 channels.
V1a receptors mediate systemic vasoconstriction, playing a significant role in cardiovascular homeostasis.
Plasma levels of vasopressin are often found to be inappropriately low in states of vasodilatory shock, such as sepsis.
The hormone's clinical utility is heavily focused on critical care settings for managing hypotension and shock states.

Table of Contents

1.Overview

Vasopressin, also known as antidiuretic hormone (ADH), is a cyclic nonapeptide synthesized in the hypothalamus and stored in the posterior pituitary gland. It serves as a primary mediator of water homeostasis and cardiovascular tone. Its release is tightly regulated by osmoreceptors that detect changes in plasma osmolality and baroreceptors that respond to fluctuations in blood volume and pressure.

2.Mechanism of Action

The physiological actions of vasopressin are mediated by three distinct receptor subtypes: V1a, V1b, and V2. The V1a receptor is predominantly located in vascular smooth muscle, where its activation leads to vasoconstriction. The V1b receptor (also known as V3) is primarily found in the anterior pituitary and is involved in the regulation of hormone secretion.

3.Why Researchers Study It

Research into vasopressin spans from basic molecular biology to clinical critical care. Scientists study the signaling pathways of its receptors to understand how mutations lead to disorders like nephrogenic diabetes insipidus. Additionally, there is significant interest in the role of vasopressin in neuro-hormonal circuits and its potential as a therapeutic agent in various shock states.

4.Pharmacology & Molecular Identity

Pharmacologically, vasopressin acts as a potent vasoconstrictor and antidiuretic. It is known that V2 receptor activation increases water permeability in the renal collecting duct by promoting the insertion of aquaporin-2 water channels into the apical membrane. While the signaling pathways are well-characterized in vitro, the precise clinical dosing and timing in complex human pathologies remain subjects of ongoing investigation.

5.Human Research Evidence

Human evidence is robust regarding the hormone's role in physiological homeostasis. Clinical studies have extensively evaluated the use of exogenous vasopressin in patients with septic shock and other forms of vasodilatory hypotension. Observations indicate that vasopressin infusion can decrease the requirement for catecholamines in these patients, though clinical outcomes depend on the timing and context of administration.

6.Preclinical Research

Preclinical research has been instrumental in identifying the receptor subtypes and their respective G-protein coupling mechanisms. Animal models have provided foundational data on how vasopressin influences blood pressure, hepatic metabolism, and brain edema. These studies continue to refine our understanding of the cross-talk between vasopressin signaling and other hormonal systems.

7.Safety & Research Limitations

Clinical use of vasopressin is limited by its potent vasoconstrictive properties, which can lead to tissue ischemia if not carefully monitored. Evidence suggests that excessive or inappropriate use may result in adverse cardiovascular effects. Furthermore, the complexity of its receptor distribution means that systemic administration can have off-target effects, necessitating precise clinical oversight.

8.Evidence Quality & Research Gaps

Despite extensive knowledge, gaps remain regarding the long-term effects of vasopressin modulation in chronic conditions. There is also a need for more definitive data on the optimal timing of initiation in various shock states to improve patient outcomes. Additionally, the role of vasopressin in non-classical pathways and its interaction with other neuroendocrine systems continues to be an area of active inquiry.

9.Frequently Asked Questions

10.References

1.Authors not listed. Vasopressin. . 2006.PMID: 29999710
2.Sacha GL, Bauer SR. Optimizing Vasopressin Use and Initiation Timing in Septic Shock: A Narrative Review. Chest. 2023 Nov. DOI: 10.1016/j.chest.2023.07.009.PMID: 37479058
3.Sparapani S, Millet-Boureima C, Oliver J, Mu K, Hadavi P. The Biology of Vasopressin. Biomedicines. 2021 Jan 18. DOI: 10.3390/biomedicines9010089.PMID: 33477721
4.Moodley N. Copeptin analysis in endocrine disorders. Frontiers in endocrinology. 2023. DOI: 10.3389/fendo.2023.1230045.PMID: 37859988
5.Jan MY, Moe SM, Adebiyi O, Chen J, Powelson J. Vasopressin for Post-kidney Transplant Hypotension. Kidney international reports. 2022 Jun. DOI: 10.1016/j.ekir.2022.03.035.PMID: 35694563
6.Holmes CL, Russell JA. Vasopressin. Seminars in respiratory and critical care medicine. 2004 Dec. DOI: 10.1055/s-2004-860984.PMID: 16088512
7.Zeynalov E, Jones SM, Elliott JP. Vasopressin and vasopressin receptors in brain edema. Vitamins and hormones. 2020. DOI: 10.1016/bs.vh.2019.08.015.PMID: 32138953
8.Holmes CL, Walley KR. Vasopressin in the ICU. Current opinion in critical care. 2004 Dec. DOI: 10.1097/01.ccx.0000144769.19213.0c.PMID: 15616384
9.Pelletier JS, Dicken B, Bigam D, Cheung PY. Cardiac effects of vasopressin. Journal of cardiovascular pharmacology. 2014 Jul. DOI: 10.1097/FJC.0000000000000092.PMID: 24621650
10.Choong K. Vasopressin in Pediatric Critical Care. Journal of pediatric intensive care. 2016 Dec. DOI: 10.1055/s-0036-1583282.PMID: 31110903

Compound Command Center

Linked Research Evidence (0)

Published studies and registry summaries. Trial registration alone is not evidence of efficacy.

No linked research articles yet.